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ABSTRACT 
Use of the Polymerase Chain Reaction 
in the Detection of 
Bovine Leukosis 
by 
Emma Jane Kelly, Master of Science 
Utah State University, 1992 
Major Professor: Dr. M. Keven Jackson 
Department: Animal, Dairy, and Veterinary Sciences 
A diagnostic test for bovine leukosis was developed using 
the polymerase chain reaction (PCR) to amplify a 375 base pair 
region in the gag gene of the proviral genome. 
Blood samples were collected from 3 adult Holstein cows 
shown to be infected with bovine leukosis virus (BLV) by the 
agar-gel immunodiffusion (AGID) technique. The 3 samples were 
mixed and the composite blood was used to inoculate 10 cows. 
Five of the cows were inoculated with 0.1 ml of blood, and the 
other cows were inoculated with 1 ml of blood. Five of the 
cows were negative for BLV by AGID and PCR on the day o f 
inoculation, and the other five cows were positive for BLV on 
the day of inoculation. 
The 10 cows were bled on day 1 (day 0 being the day of 
inoculation) and day 7 post-inoculation, and every 2 weeks 
subsequently until 3 months post-inoculation. samples were 
stored until the end of the study, at which time the AGID and 
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PCR t ests were performed. 
The 5 cows that were positive on day 0 remained positive by 
AGID and PCR for the remainder of the study. 
Three cows became AGIO-positive 3 weeks post-inoculation, 
and two cows seroconverted 5 weeks post-inoculation. The time 
of seroconversion did not correlate with the volume of viral 
inoculum. In comparison, the PCR consistently detected 
infection sooner than the AGID: by day 7 post-inoculation all 
5 cows were BLV-positive as determined with the PCR test, and 
remained positive until the end of the study. 
The r esults indicate that under the experimental 
conditions, bovine leukemia virus infection in cattle can be 
detected as much as 2 to 4. weeks earlier by PCR than by AGID. 
(84 pages) 
INTRODUCTION 
The purpose of this research was to develop a diagnostic 
test for bovine leukosis virus (BLV) using the polymerase 
chain reaction (PCR), then to compare the PCR with agar-gel 
immunodiffusion (AGID) . The hypothesis was that the PCR would 
be more sensitive and specific than AGID. 
The ideal diagnostic test to detect BLV infection would 
have the following properties: 
1. High sensitivity and specificity. A test that would detect 
the actual virus or antigen would be preferable since AGID 
detects anti-BLV antibodies. 
2. A quick and easy procedure that could be applicable to 
large scale BLV detection. 
3. Relatively inexpensive. 
4. Able to distinguish colostral antibody from that acquired 
by natural infection. A test to detect the actual virus would 
be preferable since young animals with colostral antibody are 
not infected with the virus, and would, therefore, not give 
false positive test results. 
5. Able to detect antibody or antigen in milk, including bulk 
samples from herds with a low BLV prevalence. 
A test using the polymerase chain reaction (PCR) was 
developed to detect BLV infection. PCR was utilized to amplify 
a specific DNA sequence of the bovine leukosis provirus for 
subsequent detection by gel electrophoresis. This procedure 
has the potential to be a very sensitive test, able to be 
performed on blood or milk, and highly specific for BLV with 
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no false positives due to colostral antibody. 
The radioimmunoassay (RIA) and enzyme-linked 
immunoabsorbent assay (ELISA) tests are very specific. 
However, the RIA is not quick and easy to perform and the 
ELISA, though easy to perform, may detect a trace of positive 
contaminating serum in a negative sample. Neither test can 
differentiate colostral antibody from natural infection, nor 
detect antibody in bulk tank milk. The AGID test is quick, 
easy and inexpensive, but lacks sensitivity, cannot 
distinguish colostral antibody and cannot detect antibody in 
milk, as a rule. The other serologic tests mentioned in 
passing have not been sufficiently used and evaluated. The 
current methods used to detect the actual virus generally use 
tissue culture, which is expensive and laborious. 
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REVIEW OF LITERATURE 
Bovine Leukosis 
Bovine leukosis has been described in the literature for 
many years. The first documented case was in Germany in 1871 
(1). Most early descriptions of the disease were in Europe, 
though several cases occurred in the United States . 
Forms of the Disease 
There are 2 forms of the disease: enzootic bovine leukosis 
and sporadic bovine leukosis. Sporadic bovine leukosis is 
uncommon and affects animals under 3 years of age (2). There 
are 3 forms of· sporadic bovine leukosis: the juvenile form 
that affects calves less than 6 months old, the thymic form in 
animals less than 2 years of age, and the cutaneous form in 
animals of 1-3 years of age (2) . The cause of sporadic bovine 
leukosis is unknown. The more common form is enzootic bovine 
leukosis (or adult multicentric leukosis) in which disease 
occurs in adult animals. The etiologic agent of enzootic 
bovine leukosis is bovine leukemia virus (BLV) in the family 
Retroviridae, subfamily Oncovirinae (3,4). Development of 
clinical disease is rare. Persistent lymphocytosis is a benign 
reaction to BLV (2); cattle may later develop lymphosarcoma or 
may remain nonclinical for the remainder of their lives. 
Persistent lymphocytosis is not a precancerous condition. 
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Prevalence 
Enzootic bovine leukosis is present worldwide, with some 
areas having a higher prevalence, such as parts of South 
America, North America, Asia, and much of Europe. It is 
estimated that at least 20% of the adult dairy cattle in the 
USA are seropositive to BLV (2). However, there are very few 
BLV-positive cattle in the United Kingdom, New Zealand, and 
Australia (2). Infection in beef cattle is much less common 
(approximately 1-20%) (4). Mortality due to the disease is 
quite low (2-5%) (2). 
Species Affected 
In nature, cattle are the only host species for BLV (2,4). 
Experimentally, the virus has been transmitted to sheep 
(5,6,7,9,10,11,12), goats (8), and chimpanzees (13). BLV can 
infect cats, dogs, and rabbits (14). It was concluded (15) 
that experimental animals (mice, guinea-pigs, and hamsters) 
are not suitable for studies of bovine leukosis because 
infection with BLV in these animals produced no characteristic 
lesions. Attempts to transmit it to swine (16) have been 
unsuccessful. Olson and Driscoll (17) examined the 
relationship between cases of human and bovine leukemia to see 
if there is a correlation between the two. They found that 
human beings in close contact with potentially BLV-infected 
cattle do not develop antibodies to BLV (17). In a similar 
study, sera from humans likely to be exposed to BLV (animal 
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caretakers, laboratory personnel, veterinarians) were tested 
for BLV (18): no specific antibodies to BLV were found. 
However, the authors reported that BLV does grow in human 
cells. Another study was performed (19) to see if there was a 
relationship between human acute lymphoid leukemia in 223 
people in Iowa and exposure to dairy cattle and drinking of 
raw milk. The authors concluded that there was no 
relationship. 
Nature of the Virus 
The virus is present in host B lymphocytes (2) and its RNA 
genome is copied into a DNA molecule by a viral enzyme called 
reverse transcriptase (RNA-dependent DNA-polymerase) (4). This 
DNA enters the host cell nucleus and becomes permanently 
integrated into the host cell DNA, and is, therefore, 
multiplied as host cell division occurs (2,4). The viral 
infection is permanent because of its location within cells 
( 2) . The virus does not need to multiply for survival or 
transmission because it is permanently integrated in the B 
lymphocytes, so that when the cell divides the viral DNA is 
present in the daughter cells. The infected animal sheds 
infected cells even though it may develop specific antibody 
(2,4}. Bovine leukemia virus is a retrovirus, in the subfamily 
Oncovirinae (20). The genome of the virus includes 3 genes 
(20): 
1. The gag gene (group-specific antigen) which encodes the 
internal structural virion core proteins known as plS, p24, 
6 
and pl 2 . 
2. The po l gene (pol ymerase) which encodes the reverse 
transcriptase enzyme. 
3 . The env gene coding for the virion envelope glycoproteins 
(envelope) known as gp60 and gp51. 
The virus is a c-type particle, by virtue of morphology of the 
virus seen within infected cells by electron microscopy (20). 
Retroviruses are RNA viruses with a linear single-stranded 
genome (20). Other viruses in the subfamily Oncovirinae affect 
chicken, swine, and cats (20). The retrovirus family also 
includes 2 other subfamilies, the Lentivirinae and the 
Spumavirinae (20). The lentiviruses include Bovine 
Immunodeficiency Virus (BIV), as well as the causative agent 
of human AIDS. The spumaviruses are nonpathogenic (20). 
Rice, Stephens, and Gilden (21) sequenced a tumor-derived 
bovine leukemia provirus and summarized the BLV genome. From 
the 5' end, the BLV genome can be represented as follows (21): 
R+U5--GAG--POL--ENV--pX--U3+R 
1. R represents a sequence of nucleotides repeated at the 5 1 
and 3' extremities of the viral RNA. 
2. U5 and U3 are sequences unique to the 5' and 3 1 end of the 
genome, respectively. 
3 . The long terminal repeat is a combination of RU5 and UJR. 
4. pX is the region between the 3 ' end of the env gene and the 
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5' end of U3. It is a region of 1817 nucleotides which encodes 
genes regulating virus expression. 
Response to Viral Exposure 
Upon exposure to virus, some animals do not become 
infected, some animals become permanently infected and form 
antibodies (latent carriers), while others become permanently 
infected, form 
lymphocytosis (2). 
antibodies, and develop 
Finally, the minority of 
persistent 
the exposed 
animals become infected, seroconvert, may or may not have had 
persistent lymphocytosis, and develop lymphosarcoma (2). The 
incidence of neoplasia is very low, 5% or less (2). 
It appears that the outcome of infection may be genetically 
determined (22). Therefore, an individual animal's response to 
exposure to the virus may depend on its level of genetic 
resistence or susceptibility, as well as the infective dose of 
virus, the virulence of the virus, and the animal's immune 
status. 
Experimentally, the infection first spreads to the spleen 
(virus recoverable 8 days post-infection) , then virus is 
present in peripheral blood leukocytes a week later (2 weeks 
post-infection), and antibodies are detectable in serum 5-6 
weeks after infection (23). In this experiment, calves of 
approximately 15 months of age and negative for antibodies to 
BLV were inoculated subcutaneously with approximately 250,000 
lymphocytes from a BLV positive steer. In natural infections, 
seroconversion occurs 3-4 months after a negative adult animal 
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is placed in a positive group (2). Passive (or colostral) 
immunity persists fo r 2-7 months (2). 
Economic Loss Associated with Di sease 
Though enzootic bovine leukosis is associated with a very 
low mortality, there is considerable economic loss due to the 
disease. Direct losses associated with the virus include 
decreased milk production and condemnations at the slaughter 
house (24). These losses are minor compared to the indirect 
losses due to the political and social stigma associated with 
the disease (24). Many countries without the disease will not 
import cattle without a negative blood test (2). In the United 
States, approximately 44 million dollars is a conservative 
estimate of the annual cost of the disease (24). Death losses 
due to lymphosarcoma will be more significant in certain dairy 
h e rds tha t keep pedigreed animals or seedstock. These 
pedigreed animals are more valuable than commercial animals 
and have a higher average age. 
Transmission of the Virus 
Transmission of the virus is mainly horizontal via infected 
lymphocytes, such as in blood, milk, and tumor masses (2). BLV 
has also been detected in nasal and tracheal washings (25). In 
utero transmission occurs, but is much less significant (26). 
Jacobsen et al. (26) found that 4.7% of calves in one herd and 
3.4% of calves in another herd born to BLV-seropositive cows 
were seropositive at birth. This indicates a low incidence of 
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in utero BLV transmission. An earlier study (27) reported that 
18% of calves born to BLV-positive cows were BLV-positive 
before they received colostrum. The authors (27) found that 
most of the cattle that became infected with BLV did so after 
exposure to the adult herd. During their early life, they were 
protected against horizontal transmission by colostral 
antibody (27). Natural transmission seems to require close 
contact between infected and susceptible animals for a 
prolonged period of time in order for infected lymphocytes to 
enter the skin of the susceptible animal (4). Insects have 
been shown to transmit the virus (28,29,30,31). Iatrogenic 
transmission of the virus has occurred via blood associated 
with husbandry 
dehorning (32), 
rectal palpation 
and veterinary 
ear tattooing 
( 36 , 37). It 
practices such as gouge 
(33), needles (34,35), and 
is felt that calves are 
susceptible to BLV infection via milk if they are born to a 
BLV-negative dam and, therefore, are not protected by colos-
tral antibody. However, a recent preliminary study (38) 
suggests that the dose of BLV-infected lymphocytes normally 
present in milk, which is considerably less than in an equal 
volume of blood, may be insufficient to infect calves. It has 
been shown experimentally (39) that calves born to BLV 
positive cows are protected from infection by colostral 
antibodies. This is presuming that the calf did not get BLV by 
in utero transmission and receives colostrum before horizontal 
exposure to the virus. Semen, embryos used in embryo 
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transfer, sa l iva, urine, and feces do not appear to play a 
role in transmission of the virus (40) . Another report (41) 
demonstrated the noninfectivity of semen from infected bulls. 
An experiment (42) in which calves from BLV-positive dams and 
BLV-negative dams were transplanted as embryos into both BLV-
positive and negative recipients reconfirmed that transmission 
of BLV by embryo transfer occurs rarely or never. 
Inactivation by Pasteurization 
Pasteurization does inactivate the virus (43,44,45). 
Roberts et al (43) added 107 BLV-infected lymphocytes to 500 
ml of milk pooled from BLV-free cows, and heat-treated the 
milk at temperatures from 40°C to 65°C for 70 seconds. Sheep 
were then inoculated with the heat-treated m'ilk and tested for 
BLV by the AGIO test every month for 6 months. At the end of 
the 6 months, v irus isolation of BLV was attempted in all of 
the sheep. The researchers (43) found that BLV infectivity in 
infected lymphocytes was destroyed when the milk was heated at 
50°C or above for 70 seconds. This high-temperature short-time 
procedure is similar to commercial pasteurization (43). Rubino 
et al (44) studied the survivability of BLV-infected 
lymphocytes in milk. They found that BLV in milk can survive 
at least 3 days of refrigeration temperatures, and that 
variations in milk constituents such as fat, protein, total 
solids, and cells had no significant effects on BLV 
survivability (44). However, pasteurization at 63°C for 30 
11 
minutes did inactivate the BLV-infected lymphocytes {44). The 
c onclus ions of a study in Australia {45) were that Australian 
commercial pasteurization procedures {63°C for 30 minutes or 
72 ° to 73 °C for 15 to 20 seconds) are sufficient to destroy the 
infectivity of BLV and BLV-infected lymphocytes in milk. 
Diagnosis and Clinical Disease 
Confirmation of BLV infection has 
demonstrating 
development of 
serology. 
persistent lymphocytosis, 
lymphosarcoma, by virus 
been made by 
by confirming 
isolation, or by 
Lymphocytosis is an increase in the total white blood cell 
{WBC) count. The normal bovine WBC count ranges from 6,000 
cells/microliter to as high as 15,000 cells/microliter, and 
the percentage of lymphocytes is approximately 60%. Cows with 
persistent lymphocytosis have a greatly increased percentage 
of lymphocytes, especially immature forms {2), as well as an 
elevated total WBC count. Before the viral etiology of the 
disease was known, persistent lymphocytosis was used to diag-
nose bovine leukosis. Lymphocyte "keys" correlating total 
number of leukocytes and percentage of lymphocytes were used 
to assess the degree of suspicion for leukosis {46). 
Currently, much less emphasis is placed on this finding. 
If neoplasia develops, depending on its location, clinical 
findings may provide a presumptive diagnosis. Sometimes 
clinical signs are very nonspecific, such as decreased milk 
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production and decreased appetite. Unilateral or bilateral 
exophthalmus may be seen with retrobulbar tumors. 
Occasionally, the lymphosarcoma will be intraocular (47), in 
which case there may be redness and epiphora rather than 
exophthalmus. Lymphosarcoma involving the uterus or pelvis may 
be palpable on rectal examination. Posterior paralysis 
unassociated with parturition may be due to spinal leukosis. 
Lymphadenopathy may be visible if external lymph nodes are 
involved. Melena andjor sudden death may be due to abomasal 
ulceration associated with lymphosarcoma. Definitive diagnosis 
requires histologic examination of a tumor sample obtained by 
biopsy or necropsy. 
In cattle that develop neoplastic disease, the incubation 
period is usually 4-5 years (2), so that adult cattle between 
4 and 8 years of age are most commonly affected (2,4). Lympho-
sarcoma most commonly develops in the abomasum, heart, 
visceral lymph nodes, peripheral lymph nodes, and uterus 
(2,4), though lesions can form in any organ. The course of the 
disease varies from subacute to chronic (2). Clinical signs 
depend on the affected organ(s), and include nonspecific as 
well as specific signs, as already mentioned. In 1100 field 
cases (48), the clinical signs seen with the highest frequency 
included weight loss, decreased milk yield, external 
lymphadenopathy, decreased appetite, internal lymphadenopathy, 
posterior paresis, fever, respiratory signs, bilateral 
exophthalmus, diarrhea, constipation, unilateral exophthalmus, 
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and cardiovascular disease. 
Virus isolation requires inoculation of suspect leukocytes 
onto lamb spleen cells (or other appropriate cells) . If there 
is viral growth, the virus may be identified by electron 
microscopy, fluorescent antibody test (FAT), enzyme-linked 
immunoabsorbent assay 
syncytial-infectivity 
(ELISA), radioimmunoassay (RIA), 
assay (2). Tissue culture work 
or 
is 
expensive and laborious, and so serologic diagnosis is usually 
performed. 
Many serologic tests have been described in the literature. 
These tests rely on the presence of antibody to bovine 
leukosis present in the animal's blood or milk. Because the 
virus establishes a permanent infection, there is constant 
antigen production and antibody response (4). Calves that 
drink colostrum from BLV-positive cows develop passive anti-
body titers that persist for 2-7 months (2), so care must be 
taken in interpreting test results from calves. 
Some the serologic tests that have been used to diagnose 
BLV found in the recent literature are as follows: 
1. Agar gel immunodiffusion test (AGID) (3,49,50,51,52). 
2. Radioimmunoassay (RIA) (3,49,50,51). 
3. Enzyme-linked immunoabsorbent assay (ELISA) ( 3, 53, 54) . 
4. Protein immunoblot test (55). 
5. Early polykaryocytosis inhibition test (56). 
6. Anticomplement immunofluorescence (3). 
7. Complement fixation (3). 
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8 . Indirect immunoperoxidase test (3). 
9. Micro counter-current immunoelectrophoresis test (3). 
10 . Indirect hemagglutination test (3) . 
11. Chemoluminescence (3). 
12. Immunofluorescence, direct and indirect (3). 
13. Serum neutralization test (3). 
The 3 serologic tests that have been used the most are the 
AGIO, the RIA, and the ELISA. The protein immunoblot test was 
claimed to be more sensitive than the AGIO test (55); however, 
little other mention has been made of it. The early 
polykaryocytosis inhibition test is as sensitive as RIA, but 
requires tissue culture (56). In tests involving complement 
fixation, there was interference from anti-complement activity 
of positive BLV sera (3). Immunofluorescence was found to be 
too laborious for routine work (3). 
The AGIO test is easy to perform, and has extensively been 
used as a screening test to diagnose herd infection. It is not 
considered accurate enough for individual animals because of 
false positive reactions (2). This is the test recognized by 
most governments that have cattle importation requirements. 
Test kits are commercially available. BLV infection can be 
detected with this test within 2-3 months after virus exposure 
(4). The disadvantages of the AGIO test include the fact that 
it cannot detect BLV in individual or bulk tank milk samples 
(52), it cannot distinguish colostral antibody from antibody 
acquired by natural infection (49), and, as previously 
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me ntioned, the re are fal s e positive reactions ( 2 ). 
There a r e 2 major a ntige ns of the bovine leukosis v irus 
that are used to detect antibody in suspect sera from cattle 
and sheep (51). Antigen p24 is a 24,000 dalton, ether-
resistent, nonglycosy lated polypeptide of the virion core. 
Antigen gp51 is a 51,000 dalton, ether-sensitive, glycosylated 
protein of the virion envelope (51). In most animals, the 
antibody titer to gp51 is higher than the titer to p24, so 
that immunodiffusion tests must be conducted with gp51 
antigen. However, Gauthier et al (56) indicate that some 
infected cattle react solely with p2 4 or gp51 antigens, which 
favors use of a duel antigen. Most commercial AGIO testkits 
have both antigens. AGIO is more s ensitive than complement 
fixa tion and less sensitive than enzyme-linked immunosorbent 
a s say , v irus neutralization, and radioimmunoassay (pr esumably 
because higher antibody concentrations are required to 
visualize the precipitation lines in the AGIO test than would 
be necessary to detect antibody by the other immunologic 
techniques) (51) . 
The first RIA was developed for p24 (the major internal 
protein), but there is now an RIA for the major surface 
glycoprotein (gp51) (51). Gp 51 RIA is the more sensitive test 
(51). The RIA test is not accepted as a general diagnostic 
test because it is not quick and easy to perform, but it is 
still one of the most sensitive tests for detecting BLV 
antibodies (51). 
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A study was done (50) to compare the sensitivity and 
s pecificity of AGID and RIA. The sensitivity of AGID compared 
to gp51 RIA was 85.1% when the test was read at 48 hours and 
94 . 6% at 7 2 hours. The specificity increased from 92.2% at 48 
hours to 9 6 .4 % at 72 hours. Reading the AGIO at 72 hours also 
clarified most reactions that were questionable at 48 hours 
due to haze around the test serum well (50). 
Another study (49) was performed to compare the length of 
time that colostral antibodies were detectable by RIA and AGID 
in 24 calves. With AGID, average time that colostral 
antibodies were detectable was 3.8 months (minimum 2 months, 
maximum 6 months). With RIA, the average time was 6.0 months 
(minimum 4 months, maximum 9 months). It can be concluded that 
RIA detects colostral antibodies in older calves later than 
the AGID test does. This is a disadvantage because it is 
unclear if a positive test result is due to true infection or 
colostral antibodies in older calves. That is, there is a 
longer period of uncertainty with the RIA test. 
The ELISA test has been used in the diagnosis of BLV. 
Portetelle and Mammerickx (53) reported that it is very 
sensitive and specific and went so far as to say that the 
ELISA using a monoclonal antibody to bind gp 51 antigen could 
be the most sensitive and practical method for large-scale 
detection of BLV. According to Mammerickx and Portetelle, the 
ELISA can detect BLV in individual cow milk samples (which is 
not possible with AGID because the antibody level is lower in 
17 
milk than in serum). However, in herds with infection rates 
lower than 5-10%, the ELISA cannot detect antibody in bulk 
milk tank samples. Like the other serologic tests, the ELISA 
cannot differentiate colostrally acquired maternal antibodies 
from active antibodies. Another disadvantage that the ELISA 
shares with the RIA is that it is so sensitive that it can 
detect residual colostral antibodies months later than the 
less sensitive AGIO. Contamination of negative sera with a 
trace of positive serum can be detected by ELISA. There has 
also been an ELISA developed to detect antibody to 
glycoprotein 60 (gp 60) antigen, which is an envelope antigen 
(57). 
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The Polymerase Chain Reaction (PCR) 
The PCR i s a procedure for in vitro amplification of a 
specific segment of DNA (58,59). Within hours, over a million 
copies of the DNA can be synthesized (59), and this greatly 
increases the sensitivity of detection of viruses. 
Concept of PCR 
PCR is a three-step process involving denaturation of 
double strand DNA to single strands by breaking the hydrogen 
bonds that hold the 2 strands together, annealing of primers 
to these separated strands, and synthesis of DNA from the site 
of primer attachment (60). Heating to 90-100°C is the method 
used to denature the DNA, though there are other means to do 
this (61) . Synthesis of new strands of DNA is catalyzed by a 
DNA polymerase that sequentially adds nucleotides 
complementary to the template strand to the 3 ' end of the 
annealed primer (61). After repeated cycles of PCR, the 
amplified DNA fragment can be identified by gel 
electrophoresis, among other methods. 
Primers 
The primers are segments of synthetic single-stranded DNA, 
usually 20-30 bases in length (oligonucleotides) (60). Two 
primers are used and each primer is complementary to a 20-30 
nucleotide sequence on one of the original DNA strands immed-
iately upstream or downstream to the sequence of interest 
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(61). The primers hybr i dize to opposite strands of the target 
sequence and are oriented so that DNA synthesis proceeds 
across the region between primers (62). The primers also bind 
to the extension products allowing DNA synthesis from these as 
well as from the original DNA, so that each amplification 
cycle results in doubling of the amount of DNA synthesized in 
comparison to the previous cycle (62). The result is an 
exponential accumulation of specific target fragments: 
approximately 2", where n=number of amplification cycles 
performed (62). A single copy of DNA can be increased up to 
1,000,000 copies after only 30 cycles (61). A concentration of 
between 0.1 and 0.5 uM of each primer is usually effective 
( 63) . At these concentrations, the primers are present in 
excess so that they are more likely to anneal to the 
dissociated strands than the strands are to reanneal to each 
other (61). However, use of higher concentrations of primers 
increases the possibility of mispriming, accumulation of 
nonspecific products, and primer-dimers (63). Obviously, 
nonspecific products use up primers and other reaction 
components, thereby lowering the yield of the target sequence. 
The use of higher temperatures for 
extension increases the specificity 
primer annealing and 
of the amplification 
reaction, which in turn increases the yield of the desired 
product (64). 
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There are several guidelines to aid in primer selection 
(6 2 ' 63 ): 
1. Primers should have an average G+C (guanosine+cytosine) 
nucleotide composition of 50-60%. 
2. Primers should have a random base composition; that is, if 
possible, no stretches of polypurines (polyadenosine or 
polyguanosine) or polypyrimidines (polythymidine or poly-
cytosine). 
3. Ensure the primers are not complementary especially at the 
3 1 ends because this promotes primer-dimer artifacts. Primer-
dimers are template-independent artifacts that decrease yield 
of desired product. 
4 . If possible, palindromic sequences within primers should be 
avoided because of the potential for a primer to anneal to 
itself. 
5 . Significant secondary structure within the template DNA in 
the area of the target sequence should be avoided. 
6. To ensure that the 3' end of the primer anneals strongly to 
template DNA, primers should be chosen with a 3' C or G (3 
hydrogen bonds are more stable than the 2 hydrogen bonds 
between A and T) (65). The 3' end of the primer is where 
extension is initiated. 
Reaction Conditions 
Once the DNA sequence to be amplified and appropriate 
primers have been selected, the procedure is fairly simple. 
Theoretically, there is no need to extract the DNA from the 
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cells because the primers should be able to find the target 
sequence even in a mixture of DNA, proteins, and lipids (60). 
The quantity and quality of the DNA to be amplified need not 
be high: the sample should contain at least one copy of the 
target sequence, and the concentration of impurities should 
not be enough to inhibit polymerization (62). Proviral DNA, 
Taq polymerase, the 4 deoxynucleotide triphosphates, buffer 
containing magnesium, and the 2 primers are mixed together 
usually in a microcentrifuge tube. The size of the 
microcentrifuge tube will be dictated by the size of the 
sample holes in the heating block of the thermal cycler, if a 
thermal cycler is used rather than preset water-baths. The 
usual sample volume is 100 ul, and typically the sample is 
overlaid with 100 ul of mineral oil to prevent evaporation of 
sample during the cycles of denaturation-annealing-extension. 
The four dNTP' s or deoxynucleotide triphosphates (dATP, 
dCTP, dGTP, and dTTP) should be used at the same concentration 
to minimize misincorporation ( 62, 63) . The recommended 
concentration of dNTP per reaction is between 20 and 200 uM of 
each (63). Misincorporation is when the wrong nucleotide is 
added to the growing DNA chain. For example, dATP may be added 
to the nascent chain opposite cytosine on the template strand. 
A-C is not a Watson-crick pair and dGTP would be the correct 
nucleotide to pair with the template strand cytosine. Misin-
corporation is promoted when the concentration of one dNTP is 
low relative to the others or when the dNTP concentrations are 
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be l ow 1 uM ( 63 ). 
The magnesium concentration in the buffer is important 
because it can affect polymerase enzyme activity, primer 
annealing, strand dissociation temperatures, product 
specificity, and primer-dimer formation ( 63) . It is 
recommended that each PCR reaction contains 0. 5 to 2. 5 rnM 
magnesium above the total dNTP concentration, because the Taq 
DNA polymerase used in PCR has a requirement for free 
magnesium above that boun~ by primers, dNTPs, and template DNA 
(6 3 ). 
The standard buffer used for PCRs involving genomic DNA 
contains SOrnM KCl, 10 rnM Tris-HCl (pH 8 . 4), 1.5 rnM MgCl2 , and 
100ugjml of gelatin ( 62) . The KCl facilitates primer annealing 
(63) . The gelatin helps stabilize the enzyme, but it is not 
always essential for the success of the protocol (63). Bovine 
serum albumin and nonionic detergents (Tween 20 or Laureth 12) 
can be used instead of gelatin (63). 
Taq DNA Polymerase 
Taq polymerase is a thermostable DNA polymerase enzyme from 
the thermophilic bacteria Thermus aquaticus (58) that 
synthesizes DNA by assembling the 4 nucleotides in a 5' to 3' 
direction (60). The DNA polymerase enzyme previously used was 
destroyed during the heat denaturation step and fresh enzyme 
had to be added for each cycle (60). The Taq polymerase is a 
major advance allowing automation of PCR, that is, the use of 
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the rmal cyclers (60). The elevated temperatures at which PCR 
with Taq polymerase can be performed have increased the 
specificity of priming (65). The optimal concentration for Taq 
polymerase is approximately 2 units/100 ul reaction (62). 
The enzyme has a high temperature requirement (temperature 
optimum of 80°C), it does not have single-stranded 3 1 -5 1 
exonuclease activity (at least in vitro), it requires a 
divalent cation cofactor (Mg2+ or Mn2+), and it has high 
activity in Tris-hydrochloride buffer, pH 7.8 (66). Low levels 
of monovalent cations (NaCl and KCl) stimulate catalytic 
activity of the enzyme, but above 100 mM these salts inhibit 
the activity of Taq polymerase (66). The enzyme requires all 
four dNTP 1 s for good catalytic activity (66). Tindall and 
Kunkel (67) studied the fidelity of DNA synthesis by Tag 
polymerase. The fidelity of Thermus aquaticus DNA polymerase 
at high temperatures was found to be similar to or better than 
the fidelity of other exonuclease-deficient DNA polymerases at 
37°C (67). Taq polymerase is less accurate than the Klenow 
fragment of E.coli DNA polymerase 1, however (67). This can at 
least partially be explained by the fact that the Klenow 
polymerase does possess single-stranded 3 1 -5 1 exonuclease 
proofreading activity (67). Using two fidelity assays, it was 
determined ( 67) that Taq polymerase produces single-base 
substitution errors at a rate of 1/9,000 and frameshift errors 
at a rate of 1/41,000. Taq polymerase is fast and processive 
(68): at 70°C the enzyme polymerized at a rate of 
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approximately 60 nucleotides per second, and, at substrate 
excess (0.1:1 molar ratio of polymerase to primer/template), 
most primers were completely extended before extension was 
started again on new primers. 
Taq polymerase was found (68) to have applications in DNA 
sequencing: 
1. It works over a broader temperature range than the other 
polymerases used . 
2. Hairpins in DNA that hinder polymerases and cause 
termination are not as much of a problem when Taq polymerase 
is used because the high temperatures and low salt 
concentrations in which the enzyme is active destabilize the 
hairpins. 
3. The enzyme is highly processive, lacks proofreading 
activity, and has a high turnover number. These features are 
advantageous in sequencing because they reduce pausing and 
premature termination at areas with secondary structure. 
Thermus aquaticus was first isolated in 1969 (69). It is an 
aerobic, nonsporulating, nonmotile, gram-negative rod that 
produces a yellow pigment (69). This thermophilic bacteria has 
been found in natural aquatic thermal environments (the hot 
springs in Yellowstone National Park and California), as well 
as in hot water (69). Brock and Freeze (69) reported that the 
bacteria's optimal temperature for growth was 70°C (maximum 
79°C, minimum 40°C) . 
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Cyc ling Conditions 
As already mentioned, the polymerase cha i n reaction 
involves a 3-step process: denaturation, annealing, and 
e xtension. This cycle is repeated several times and results in 
an exponential accumulation of target DNA. Different 
temperatures are used for each of the 3 steps. Either water 
baths or a thermal cycler can be used to achieve these 
temperature changes. 
Denaturation of the DNA strands is usually achieved by 
heating the sample to about 95°C for a short period of time 
(less than a minute) ( 62 , 63 ). Incomplete denaturation is the 
most likely cause for f ailure of PCR (63), so it is important 
to optimize denaturation temperature and duration. Incomplete 
denaturation allows the DNA strands to "snap back" (63). This 
means that the target sequence may be double stranded DNA and 
not available for primer binding because the primers bind to 
their complementary sequence on single-stranded DNA. G+C-rich 
targets may require higher temperatures (63) because it takes 
more energy to break the 3 hydrogen bonds between G-C pairs 
than the 2 hydrogen bonds between A-T pairs. Preceding the 
first cycle with an initial denaturation step of 3 minutes at 
93°C is recommended (62). 
Annealing is usually performed at around 55°C (range: 40°C 
to 72°C) (62,6 3 ) . 
Extension is usually performed at 72°C (63). A time of 1 
minute for each kilobase of target sequence is a good starting 
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point (6 2 ) . The number of cycles depends mainly on the 
starting concentration of target DNA ( 63 ). The more target DNA 
to start with, the fewer the number of cycles. The use of 30 
to 35 c ycles is common. 
PCR Carry -over 
Because of the extreme sensitivity of the polymerase chain 
reaction, care must be taken to avoid contamination o f 
negative samples with positive samples. This can occur by 
c ross-contami nation from the positive control or 
s ample s during the "before PCR" procedures, 
positive 
or by 
contami na t i on from already amplified DNA from previous 
experiments (that i s , by performing "before PCR" and "after 
PCR" proce dures in the same location) . There are several 
recommendations of procedures to minimize PCR carry-over ( 64) : 
1. The "before PCR" procedures (setting up the reactants in 
the microcentrifuge tube and addition of mineral oil) should 
be done in a separate area of the lab or a different room than 
the "after PCR" procedures (such as the addition of loading 
dye and loading of the samples into wells in an agarose gel 
for electrophoresis). 
2. Positive displacement pipettes should be used whenever 
possible , especially when pipetting samples that contain DNA. 
This type of pipettor does not retain any of the sample. 
3 . Reagents should be aliquoted; that is, reagents should be 
stored in small containers rather than large ones. If one vial 
of a particular reagent becomes contaminated, this 
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contamination will not affect many subsequent PCRs. To be 
absolutely safe, a new vial of dNTPs, buffer, primers, and 
enzyme can be used each time. 
4. Careful laboratory technique is essential. Working areas 
should be cleaned with ethanol often, and periodically 
depurinated with HCl. Microcentrifuge tube lids should be 
opened carefully to prevent aerosol cross-contamination. 
5 . Positive, negative, and reagent controls should be used. A 
positive control is known to contain the DNA sequence of 
interest. A negative control contains non-target DNA. A 
reagent control contains all reagents (dNTPs, enzyme, primers, 
and buffer), but no DNA. 
Uses of PCR 
The polymerase chain reaction is a fairly recent advance in 
molecular biology . Since 1986 references to methodology and 
uses of PCR have increased considerably. It has been used in 
the laboratory to facilitate research, and it is currently 
used extensively in human medicine. Its potential use in 
veterinary medicine is only recently being realised. 
Molecular Biology Research 
The polymerase chain reaction has greatly facilitated 
research in molecular biology, in both pure science and in 
science that has applications in medicine and forensics. 
Innis et al. (68) report that the polymerase chain reaction 
using Taq polymerase is highly sui ted for DNA sequencing. 
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St e p s in this procedure are as follows (68): 
1. A primer is annealed to a single-s tranded DNA temp l ate 
(th i s can be denatured double-strand DNA or DNA that is 
s ing le-stranded) . 
2. The primer is extended with DNA polymerase enzyme in 4 
separ ate reactions . Each reaction mixture contains one alpha-
labeled dNTP, a mixture of unlabeled dNTPs, and one chain-
term i nating ddNTP. 
3 . The product of each reaction is resolved on a 
polyacrylamide/urea gel 
4 . An autoradiograph is taken of each gel, and the image is 
e xamined to determine the sequence. 
Improve ments in the s peed and automation of this sequencing 
technique were made using the PCR to selectively amplify DNA. 
This is particularly suited for segments of single-copy 
genomic DNA ( 68 ). There is no need to add enzyme after each 
cycle when using thermostable Taq polymerase, and it can be 
used at high annealing and e xtension temperatures which 
increases the yield, specificity, and length of products that 
can be amplified (68). 
DNA sequencing of human genes is used to identify mutations 
and polymorphisms (70). Traditionally, if an individual is 
suspected of having a mutation, his or her genes are cloned, 
then compared to the sequence of cloned DNA from the normal 
allele (70). Also, if the person is a heterozygote rather than 
a homozygote, then the process becomes more complicated 
29 
because both alleles have to be detected (70). If the exact 
nature of the mutation is known, then hybridization with 
mutation-specific probes can be used for detection (70). 
However, these probes, known as allele-specific 
oligonucleotides (ASO), will only anneal to DNA sequences that 
match them perfectly (71). There are other approaches (70) 
that do not provide the actual sequence at the mutation site. 
Direct genomic sequencing avoids the need for lengthy cloning 
procedures and provides the actual DNA sequence of the 
mutation, but it is difficult to do because the human genome 
is complex (70). Use of the PCR to amplify the region of 
interest reduces this problem, and was used (70) to amplify 
and sequence parts of the human B-globin and fetal globin 
genes. The use of PCR in sequencing further simplifies the 
procedure because DNA purification is not required for PCR 
amplification: it can be done directly on crude cell lysates 
(71). Scharf et al. (72) used the PCR to facilitate cloning: 
by amplifying parts of the human genome by PCR and directly 
cloning into an M13 vector, the need for extensive genomic 
library construction, screening, mapping, subcloning, and 
sequencing was reduced. 
A modification of the polymerase chain reaction has been 
used to create point mutations into human ras oncogenes and to 
amplify these mutated copies (73). The PCR is used to detect 
point mutations in genes, but there is usually no positive 
control DNA that contains the mutation (73). To address this 
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problem in the ras oncogene, Rochlitz et al . (73) developed a 
t echnique using single base mutations in codons 12 and 61 of 
this gene. A normal 5' primer was used for the PCR, but the 3' 
primer contained a single base mismatch to the target codon. 
The 3 • primer also acted as the hybridization probe when 
screening for the mutation . 
The c-Kirsten ras oncogene is present in the human breast 
carcinoma cell line MDA-MB231 (74). Using the polymerase chain 
reaction to amplify parts of the human c-Kirsten ras gene and 
hybridization of this amplified DNA to oligomers specific for 
a mutation in codon 13 of the gene, researchers (74) showed 
that this mutation, which results in a change from glycine to 
aspartic acid in the c-Kirsten ras amino acid sequence, 
activates the oncogene. 
The PCR has been used to amplify DNA that has been insert-
ed into a plasmid vector (75). It is believed that any insert 
cloned in a vector can be amplified if there are available 
flanking primers and if the insert is not over 2 kb in length 
(75). 
Conventional PCR amplifies the region of DNA between the 
primers. An interesting technique known as "inverse PCR" is an 
extension of the polymerase chain reaction such that regions 
that are outside or next to an area of known nucleotide 
sequence can be amplified (76). The inverse PCR can be 
summarized as follows (76): 
1. The region to be amplified is the upstream and downstream 
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regions of DNA to a core region of known sequence. 
2. The DNA (genomic DNA, for instance) is cut using a 
restriction enzyme that does not have restriction sites within 
the core region. 
3. The DNA fragments produced by the restriction enzyme 
digestion are ligated with a ligation enzyme such as T4 DNA 
ligase to produce circularized DNA. 
4. The circularized DNA is then subjected to PCR. The primers 
are complementary to the ends of the core sequence, but are 
oriented such that the polymerase enzyme synthesizes DNA into 
the region of unknown sequence. 
5 . The major amplification product is a linear double-stranded 
segment of DNA that contains regions 3' and 5' to the core 
sequence. 
The inverse PCR allows rapid amplification of unknown 
sequences of DNA, but it is limited by the size of a region 
that can be amplified by PCR (2-3 kb) (76). 
The use of PCR coupled with sequence-specific 
oligonucleotide (SSO) probe hybridization was found to be 
effective in analysis of partially degraded DNA extracted from 
formalin-fixed, paraffin-embedded tissue specimens that had 
been stored for several years (77). The tissues were from 
patients with abnormal and normal B-globin genes, and the DNA 
that was extracted was degraded in all the samples, as 
evidenced by small segments of DNA seen on a 1.5% agarose gel 
(range: 0.1-24 kb)(77). Despite the degradation, 5'-end-
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labelled oligonucleotide probes for normal, sickle cell, and 
hemoglobin c B-globin alleles bound correctly to the DNA 
extracted from the histologic specimens (77). A similar 
procedure was performed on 40 year-old, paraffin-embedded 
tissues from patients with cervical carcinoma or squamous cell 
carcinoma of the cervix (78). Most molecular techniques 
require high-molecular-weight DNA, so the PCR has an advantage 
in that it works on small DNA segments (77, 78). There is, 
therefore, great potential to use archival formalin-fixed, 
paraffin-embedded tissues in studying diseases at the DNA 
level over time, without having to perform prospective studies 
which can take years (77,78). 
The polymerase chain reaction has been used to amplify 
small segments of mitochondrial DNA from a 7,000-year-old 
human brain (79). The cranium containing the brain was found 
in a flooded sinkhole in Florida in 1986 (79). DNA was 
extracted and purified from neural tissue, and then PCR was 
performed on it. Bovine serum albumin (2)lg/ml) and a high 
concentration of Taq DNA polymerase were necessary to overcome 
an unknown factor in the brain that inhibited amplification 
(79). Most of the DNA from the brain had degraded to a small 
molecular size (50-200 bp), which is typical of ancient DNA 
(79). The researchers (79) have noted a difference in 
amplification efficiency of ancient DNA versus modern DNA: in 
ancient DNA there is an inverse relationship between the 
efficiency of amplification and the length of the sequence to 
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be amplified. Segments o f ancient DNA up to 120 bp could be 
amplified, but segments of 200 bp could not be amplified; 
whereas with modern human DNA up to 2 kb could be amplified 
(79). 
DNA typing has been done from single hairs (80), and this 
has great potential in forensic and medical use. Most of the 
DNA in a h a ir is in the root and surrounding sheath cells, so 
that s hed hairs contain less DNA (up to lOng) than freshly 
plucked hairs (up to 200ng) (80) . At the site of a crime the 
hairs are usually shed hairs from several people and there is 
u s ually only one or a f e w hairs from any one person, s o that 
DNA typing of single, s hed hairs is more useful than typing of 
pooled, f res hly plucked samples (80). By the use of the PCR 
to ampl i fy DNA (80), DNA sequences from the root of shed and 
fre shly plucked single hairs could be detected. Collection of 
hair samples rather than blood may be useful when transport of 
blood may be difficult or in endangered or dangerous animals 
( 80). 
Another interesting application of the PCR is in 
amplification of DNA in genetically engineered microorganisms 
(81). There has been interest in introducing genetically 
engineered bacteria into the environment, and in detecting 
these bacteria in environmental samples (81) . However, there 
have been difficulties because the methods that have been used 
lack sensitivity . Steffan and Atlas (81) used the polymerase 
chain react i on to amplify a small specific region of DNA from 
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the herbicide-degrading bacterium Pseudomonas cepacia after it 
had been introduced at several different concentrations into 
env ironmental samples with mixed bacterial populations. Using 
the PCR, P . cepacia was detected at a concentration of 1 cell 
pe r gram of sediment, which is a 1, 000-fold increase in 
sensitivity over nonamplified samples (81). 
Human Medicine 
In human medicine the PCR has greatly facilitated the 
diagnosis and monitoring of many disease processes, especially 
those with a viral etiology and those involving defects in 
the genome . Serology or culture may be difficult in diseases 
caused by viruses, in which case the PCR may be very useful 
(61). The PCR may also be especially valuable in cases where 
early detection of infection is important (61). 
Recent developments in molecular biology including PCR have 
enhanced detection of mutations that may cause genetic 
disorders in man and animals (82). The PCR is used in the 
diagnosis of chronic myeloid leukemia and in following the 
course of treatment (83): it is used to amplify a sequence 
that includes an area of gene translocation (the bcr-abl 
translocation) found in patients with this disease. Patients 
with certain types of muscular dystrophy have a defective gene 
encoding the muscle protein dystrophin (84). Dystrophin mRNA 
is not easily studied because it is a large molecule and makes 
up only 0.01-0.001% of total muscle mRNA (84). The PCR was 
used to amplify dystrophin mRNA to facilitate study of the 
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dystrophin gene transcript (84) . To perform PCR on mRNA, a DNA 
copy of the mRNA is made using a reverse transcriptase enzyme 
and the PCR subsequently performed on the eDNA (84). Alpha-1-
antitrypsin deficiency can be diagnosed prenatally using the 
polymerase chain reaction (85). The polymerase chain reaction 
is one of the tools of potential use in the diagnosis of 
chronic active and recurrent herpesvirus infections (86). With 
the assistance of DNA amplification by PCR, sufficient DNA can 
be isolated from buccal epithelial cells obtained by mouthwash 
for direct gene analysis (87) . The authors believe this to 
have potential use in screening for carriers of single gene 
defects such as cystic fibrosis (87). 
Patients with B-thalassaemia have a mutation (s) in the 
Beta-globin gene resulting in decreased synthesis of the B-
globin protein. In order to characterize the mutation(s) in 
the single copy Beta-globin gene in 5 patients with B-
thalassaemia, PCR was used to amplify the genome for sequence 
analysis (88) . Two previously uncharacterized mutations in the 
Beta-globin gene were found by this method (88). 
Enterotoxins of 2 bacteria (enterotoxigenic Escherichia 
coli and Shigella) cause a significant amount of acute 
diarrhea in children in Third World countries (89) . The 
polymerase chain reaction was used to amplify the genes 
encoding the heat-stable (ST) and heat-labile (LT) 
enterotoxins of enterotoxigenic Escherichia coli (ETEC) and 
the invasion-associated loci ( ial) of the large Shigella 
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virulence plasmid (89). The procedure was then tested in a 
community in southeastern Mexico, and the authors reported 
that it was relatively rapid, straightforward, inexpensive, 
and was more sensitive than other diagnostic tests (89). 
The PCR also has applications in diagnostic pathology (90). 
For instance, PCR amplification of DNA from extremely small 
samples would be very helpful in forensic science (90). 
Bangham et al. (91) were interested in identifying the 
retrovirus associated with TSP (tropical spastic paraparesis), 
a chronic neurologic disease. Serologically, most TSP patients 
are positive for HTLV-1 (human T-cell lymphotropic virus type 
1). The authors used the PCR to amplify part of the genome of 
5 TSP patients, and sequenced part of the polymerase gene. 
They showed that the virus associated with TSP is indeed HTLV-
1, and that patients may have more than one variant of the 
virus (91). 
HIV-1 (human immunodeficiency virus-1) is the causative 
agent of AIDS (92). Infection with HIV-2 is less characterized 
and has been reported in much fewer people than infection with 
HIV-1 (92). A study was performed to find the prevalence of 
HIV-1 and HIV-2 infection in a region of West Africa (92). The 
authors used several serologic tests, as well as PCR 
amplification of proviral DNA. This region in West Africa is 
endemic for both HIV-1 and HIV-2, yet most infections were 
either exclusively HIV-1 or HIV-2. There were two patients 
with AIDS who were only infected with HIV-2, and one patient 
37 
was dually infected with HIV-1 and HIV-2 (92) . 
Several type s of PCR assays have been designed that could 
assist in investigations of neoplasia at the molecular level 
and may have use in cancer diagnosis (93). A major problem in 
treatment for cancer is recurrence of disease, probably 
because residual neoplastic cells are clinically undetectable 
(94). When the concentration of neoplastic cells is below 1% 
the cancer is very difficult to detect, yet a concentration of 
cells this low theoretically occurs in cancer patients in 
remission (94). PCR was used to amplify the area in the genome 
that encompasses the crossover sites of a chromosomal 
translocation for follicular lymphoma, t(l4;18) (94). This 
technique proved to be very sensitive in detecting residual 
neoplastic cells carrying t(14;18), more sensitive than 
Southern blot analysis, and the authors believed the technique 
to have potential in identification of subclinical cancer 
(94). 
Veterinary Medicine 
The potential uses of the PCR in veterinary medicine are 
tremendous. Deacon and Lah (95) believe that the PCR has both 
research and diagnostic applications in veterinary medicine. 
For instance, "inverted" PCR can be used to amplify regions 
outside the primers. This has been used to analyze integration 
sites of the type C retrovirus gibbon ape leukemia virus in a 
certain tumor cell line (95). The need for only a small 
specimen for PCR can be advantageous in the diagnostic lab 
38 
(95). Because PCR is so sensitive, i t may lead to earlier 
detection of bacterial and viral disease (95). PCR can be used 
to detect genetic disorders in animals, and can be used in DNA 
fingerprinting to identify individual valuable animals (95). 
PCR also has the potential to expedite genetic improvement 
programs in animals (95). 
The polymerase chain reaction has been used to amplify DNA 
sequences of pseudorabies virus (porcine herpesvirus 1) from 
infected cell cultures as well as cells of acutely infected 
pigs and latent carriers (96). Porcine herpesvirus 1 causes 
high mortality in piglets, but adult pigs usually have a 
latent infection and periodically shed the virus, causing 
recurrent infections in fetuses and piglets (96). Therefore, 
it is important to detect latent infection as well as acute 
infection. PCR amplification of the viral DNA coupled with 
detection with an oligonucleotide probe proved to be a very 
specific and sensitive method of diagnosing infection by 
pseudorabies virus (96). 
Hemophilia B is a bleeding disorder caused by absence or 
malfunction of a circulating blood coagulation glycoprotein 
known as factor IX (97). The treatment for this disorder is 
infusion of plasma rich in factor IX during each episode of 
bleeding {97). Repeated blood infusions increase the risk of 
inadvertant introduction of infectious agents into the 
patient's bloodstream (97). Gene therapy has been proposed as 
a treatment for hemophilia B, and since dogs get hemophilia B, 
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canine hemophilia B could be used as a model for human 
hemophilia B (97) . The canine factor IX gene was amplified by 
PCR and a single missense mutation in the hemophiliac sequence 
was found (97). It was theorized that the mutation has effects 
on the tertiary structure of the factor IX molecule. This 
discovery has potential to facilitate research into gene 
therapy of human hemophilia B (97). 
Bluetongue virus (BTV) is an arthropod-borne Reovirus which 
infects cattle and sheep, though clinical disease is 
predominantly seen in sheep (98). The viral genome is a seg-
mented double stranded RNA (98). Gould et al.(98) used the 
polymerase chain reaction in the detection of BTV in the blood 
of an infected sheep . Use of the PCR increased the speed and 
efficiency of identification of bluetongue infection because 
there was no need to amplify the sample by lengthy procedures 
such as egg passage or tissue culture (98). 
MATERIALS AND METHODS 
Source of Cattle and Samples 
Collected 
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Cattle used in this study were adult Holstein dairy cows 
belonging to Utah State University, Logan, Utah. The animals 
were housed at caine Dairy, Wellsville, Utah. This herd has 
been screened for enzootic bovine leukosis by AGID since 1985 
and has overall percent positive BLV titers ranging from 21.9 
in 1985 to approximately 40. Whole blood samples were 
collected from 3 cows positive for BLV by the AGID test and 
the PCR test. These cows were identified as 104, 6372, and 
6490. The 3 samples were mixed and the composite blood used to 
infect 10 cows that were negative for BLV by AGID in the 1989 
herd check. Five of the cows (278, 5720, 6618, 6756, and 
6820) were inoculated with 0.1 ml of blood, and the other cows 
(6446, 6508, 6516, 6546, and 6696) were inoculated with 1 ml 
of blood. The animals were infected by intramuscular 
injection. A minute amount of virus-infected blood was 
considered sufficient to transmit the disease since the virus 
can be transmitted by insects (28,29,30,31), which carry 
minute amounts of blood. Experimentally (34), 2 groups of 
calves were given 10 microliters and 1 microliter of whole 
blood from an infected animal and seroconverted within 8 weeks 
and 14 weeks, respectively, after inoculation. The route of 
administration (intramuscular, intravenous, subcutaneous, or 
intradermal) did not affect the rate of seroconversion. 
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Immediate l y before the 10 experimental cows were infected, 
blood samples from each were collected for the AGID test and 
for lymphocyte isolation to check if the cows were negative 
for BLV by AGID and PCR before being inoculated. Animals were 
bled from the tail vein into red top (no anticoagulant) 
vacutainer tubes for serum collection and into lavender top 
(EDTA) tubes for DNA extraction. Approximately 10 ml of blood 
was collected in each tube. 
The 10 cows were then bled on day 1 (day 0 being day of 
innoculation) and day 7 post-inoculation, and then every 2 
weeks subsequently until 3 months post-infection. At each 
collection period, blood for the AGID test and for PCR was 
collected from each cow . 
Initial Sample Treatment 
The coagulated blood was centrifuged at 1500 rpm for 10 
minutes, and the serum was decanted and frozen. The EDTA-
treated blood was layered over Histopaque-1077 (Sigma 
Diagnostics, St. Louis, Missouri), centrifuged at 1500 rpm for 
30 minutes, and the mononuclear cell layer pipetted into clean 
tubes. The lymphocytes were washed twice with 5 ml of 
phosphate buffered saline (PBS). Finally, 465 microliters of 
digestion buffer was added to each sample before they were 
frozen at -so0c. This ficoll gradient procedure was done in 
duplicate so that there were 2 of each sample of lymphocytes. 
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The Agar Gel Immunodiffus ion Test 
The AGIO tests were all performed at 1 time at the e nd o f 
the experiment to minimize variation due to reagents and 
experimental conditions. The serum samples were allowed to 
defrost and the Leukassay B test kit (Pitman Moore, Mundelein, 
Illinois) was used to test for antibodies to BLV. The test was 
run 3 times on each serum sample, and the samples run in a 
different order each time. Test serum, weak positive control 
serum, positive control serum, negative control serum, and 
a ntigen were loaded into wells in the agar. The plates were 
incubated in a humidified chamber for a total of 72 hours. The 
plates were read at 48 hours and 72 hours. If antibody was 
present, it formed a line of precipitation with the antigen. 
DNA Extraction 
The lymphocytes (with d i gestion buffer) were defrosted, 35 
ul of p r oteinase K (10 mgjml) added, and the samples digested 
in a 55°C waterbath overnight to remove most of the protein. 
Additional purification of the DNA by phenol/chloroform 
extraction was then performed. The DNA solutions were 
extracted with phenol, then with a 1:1 phenol and chloroform 
mixture, and finally with chloroform. Then 0.1 volume 0. 5M 
sodium chloride was added to each sample . The DNA was 
precipitated with 100% ethanol, washed with 70% ethanol, and 
suspended in 50 ul TE buffer, pH 8.0. The samples were then 
ready for amplification. 
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Primers Used 
The primers were from the gag region of the BLV genome 
within the area coding for the p24 protein. Both primers were 
20 nucleotides in length. The nucleotide sequence that was 
used to select the primers was from RNA Viruses (99). Primer 
1, complementary to the negative sense DNA strand, started at 
position 758 in the genome and had the following sequence: 5'-
AAGGAAATCGCAACCGCCAT-3'. Primer 2, complementary to the 
positive sense strand had the following sequence: 5'-
CTGAAGGACGAGTAGGGAGA-3 1 • This sequence is complementary to the 
20 nucleotide sequence of the BLV genome that ends at posit i on 
1133. Therefore, the region that was amplified was 375 bases 
in length {1133-7 58=37 5 ). Primers were synthesized by Dr. Tom 
Grover at the Utah State University Biotechnology Center, 
Logan, Utah. 
The Polymerase Chain Reaction 
The 3-step cycle for the polymerase chain reaction involves 
denaturation, annealing, and extension. Thermostable DNA 
polymerase from Thermus aquaticus (Promega Corporation, 
Madison, Wisconsin) was used for extension. The cycling was 
done automatically in a thermal cycler (Perkin-Elmer Cetus, 
Emeryville, California). The program used was as follows: 
1. Time delay: 3 minutes to get up to 95°C. 
2. 30 cycles of denaturation, annealing, and extension: 
A. Denaturation: 1 minute to get up to 95°C. 
30 seconds at 95°C. 
B. Primer annealing: 1 minute to get down to 55°C. 
3 0 seconds at 55°C. 
C. Primer extension: 30 seconds to get up to 72 °C. 
1 minute 30 seconds at 72°C. 
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3. Time delay: 30 minutes at 72°C. This is to ensure that 
extension is complete and that the amplified DNA is double-
s tranded (62). 
4 . Soak file: 25°C until machine turned off. 
A total volume of 100 ul per PCR reaction was as follows: 
49 .5 ul double-distilled water, 10 ul (0.25 uM) each primer, 
10 ul dNTPs (from a stock solution containing 2 mM each dNTP), 
10 ul PCR buffer (Taq DNA polymerase lOX buff er: 500 mM KCl, 
100 mM Tris-HCl (pH 8.8 at 25°C), 15 mM MgC12 , 1% Triton X-
100), 0.5 ul Taq polymerase (2.5 units), and 10 ul sample DNA. 
The PCR mix ture was overlaid with 100 ul mineral oil . For the 
reagent control, a volume of 59.5 ul of double-distilled water 
was added instead of DNA solution to make a total volume of 
100 ul. 
To increase the yield of PCR product so that it would be 
detectable by ethidium bromide gel electrophoresis, a second 
PCR was performed on each sample. After the first PCR this was 
accomplished by adding 10 ul of each primer, 0.5 ul of Taq 
polymerase, 10 ul of dNTPs, and 9.5 ul of double-distilled 
water to each sample (total added volume of 40 ul) . The 
samples were then put back in the thermal cycler for another 
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3 0 cycles of denaturation, annealing, and extension. 
Positive and Negative Control DNA 
The positive control DNA used in the PCR was extracted from 
FLK-BLV cells (fetal lamb kidney cells infected with BLV). The 
FLK-BLV cells were a gift of Dr. M.J. Van der Maaten. The 
negative control DNA was extracted from MDBK cells (a line of 
bovine kidney cells known to be negative for BLV). The MDBK 
cells were provided by Yoko Elsner in the Animal, Dairy, and 
Veterinary Science Department at Utah State University, Logan, 
Utah. Dr . Gregoire Marsolais extracted and froze the DNA from 
these cells. 
Agarose Gel Electrophoresis 
After PCR, gel-loading buffer (0.25% bromphenol blue, 0.25% 
xylene cyanol, 30% glycerol in water (100)) was added to each 
sample, and the samples were loaded onto a 1.5% agarose gel 
stained with ethidium bromide at a concentration of 0.5ugjml 
electrophoresis buffer. Agarose gel electrophoresis is a 
method for separating and purifying fragments of DNA (100). A 
1.5% agarose gel effectively separates linear DNA fragments 
ranging in size from 3 to 0.2 kb (100). The anticipated PCR 
product, 355 bp (0.355 kb), is within this range. The gel was 
attached to a power supply and an electric field generated. 
The gel was run at 40 volts for 2-4 hours then photographed on 
a UV transilluminator. One Kb DNA ladder standard size marker 
(Bethesda Research Laboratories) was run on the gel 
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s imultaneously as reference DNA of different sizes. Test 
samples and positive, negative, and reagent controls were run 
on the same gel. 
Southern Blot and Hybridization 
To ensure that the DNA band observed on the agarose gel was 
the amplified 355 bp sequence in the gag region of the BLV 
genome, the DNA band was transferred to a membrane filter 
(Gene Screen, Dupont, New England Nuclear) and hybridized with 
a probe (plasmid pUX-Gag, generous gift of David Derse) 
containing the long terminal repeat and all of the gag gene of 
BLV. This procedure was only performed on 1 gel that had kb 
ladder, reagent control, negative control, positive control, 
and 5 samples were run on it. Once the band had been 
identified as the correct band, the Southern blot and 
hybridization was not run for every gel. 
The Southern blot was done using a pressure blotting system 
(Posiblot Pressure Blotter & Pressure Control Station, 
Stratagene, La Jolla, California). Prior to Southern transfer, 
the gels were pre-treated according to the manufacturer's 
recommendations as follows: 
1. Depurination: The gel was submerged in 0.25 N HCl and 
gently shaken for 30 minutes. 
2. Denaturation: The HCl was poured off and 0.5 N NaOH, 1.5 M 
NaCl solution poured over the gel. The gel was submerged in 
the NaOH, NaCl solution for an hour. 
3. Neutralization: The denaturing solution was poured off and 
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replaced with 1M Tris pH 7.5, 1.5 M NaCl solution. This was 
poured off after an hour. 
The blotter was assembled and the blot performed according to 
the manufacturer's instructions. After the Southern blot, the 
"Gene screen" membrane onto which the DNA had been transferred 
was dried in an 80°C oven for 2 hours. 
The nucleic acid probe was labeled with alpha-32P deoxyCTP 
(New England Nuclear) with a Random Primer Reaction kit 
(Boehringr Mannheim). 
The hybridization procedure was carried out as follows 
(100): The membrane was placed in a sealable bag and 
prehybridized overnight at 42°C in 10 ml of a solution 
containing 5X sse, 5X Denhardt's solution, 25 mM KP04 , pH 7.4, 
50 ugfml salmon sperm DNA, and 50% formamide . The 
hybridization solution consisted of the prehybridization 
solution with 10% dextran sulfate. The probe was used at a 
level of 500,000 cpm per ml of hybridization solution . The 
prehybridization solut i on was removed from the bag and 
replaced with 10 ml of hybridization solution . The membrane 
was hybridized overnight at 42°C, then it was washed twice for 
15 minutes in lX sse, 0 . 1% SDS at room temperature, and it was 
then washed twice for 15 minutes in 0.25X sse, 0.1% SDS at 
hybridization temperature . Finally, the membrane was exposed 
to x-ray film. 
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The PCR Test with BIV 
Bovine leukemia virus is a retrovirus. It, like all tumor-
producing retroviruses, is in the subfamily Oncovirinae (20). 
Another subfamily of the retroviruses is the Lentivirinae 
(20), which are nononcogenic viruses causing chronic diseases 
{101). Bovine immunodeficiency-like virus (BIV) is a recently 
characterized bovine lentivirus (101). Because BIV infection 
is believed to be fairly widespread (101), and because it is 
a retrovirus, BIV-infected tracheal epithelial cells (a gift 
of Matthew Gonda) were processed for PCR using the BLV primers 
to make sure that infection with BIV would not give false 
positive results to the PCR test for BLV. The procedure 
performed on BIV was identical to that performed on BLV. 
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RESULTS 
The purpose of this study was to develop a diagnostic test 
for BLV using the PCR, then to compare the PCR test with the 
AGIO test, which is currently used extensively in the 
diagnosis of BLV. 
Five of the experimental cows (278, 5720, 6618, 6756, and 
6446) were negative for BLV by the PCR and the AGIO 
immediately before they were infected. Table 1 shows the AGIO 
results for these cows since 1985, which is when yearly 
testing for BLV was started in the Utah State University dairy 
herd. The other 5 cows were positive for BLV by the PCR and 
the AGIO just before inoculation and remained positive 
throughout the experiment. 
The AGIO tests were read at 48 and 72 hours. The results at 
72 hours were no different than the results at 48 hours. The 
test was run 3 times and the results of these 3 trials were 
very consistent. The only differences were that some weak 
positive results in some trials were strongly positive in 
others. Figure 1 is an AGIO plate showing a positive reaction, 
a weakly positive reaction, and a negative reaction. Table 2 
shows the samples that gave a weakly positive reaction in some 
trials and a strongly positive reaction in others. 
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TABLE 1-AGID test results of 5 experimental cows since 1985 
YEAR 1985 1986 1987 1988 1989 1990 
cow # 
278 
* * 
NEG NEG NEG NEG 
5720 NEG NEG NEG NEG NEG NEG 
6446 
* * 
NEG NEG NEG NEG 
6618 
* * 
NEG NEG NEG NEG 
6756 
* * * 
NEG NEG NEG 
* Cow was either not in herd or not yet born. 
NEG=Negative AGID test result 
3 
2 
Fig 1-Agar gel immunodiffusion test. Well 1 = 
weak positive, well 2 = positive, well 3 = negative. 
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TABLE 2-AGID test results that were weakly positive in one or 
two trials and strongly positive in the other trial( s) 
TRIAL 1 
WEAK POSITIVES NONE 
TRIAL 2 TRIAL 3 
5720 on 12/1 5720 on 12/1 
6820 on 11/3 
6618 on 10/7 
6446 on 10/7 
With the AGID test, 3 cows (6446, 6618, 6756) had become 
positive by 9/22/90 (inoculation date for all cows was 
9 /1/90). Therefore, these 3 cows seroconverted between 1 and 
3 weeks post-inoculation. The other 2 cows (278, 5720) had 
seroconverted by 5 weeks post-inoculation (positive for the 
firs t time on 10/7 /90). These 2 cows, therefore, seroconverted 
between 3 and 5 weeks post-inoculation . All cows remained 
positive for the remainder of the study (last testing date was 
12/1/90) after they had initially seroconverted. Table 3 
summarizes these results. With the PCR test, samples from all 
5 cows were positive by 9/8/90, which is only 7 days post-
infection (table 4). Therefore, the PCR detected infection 
with BLV between day 2 and day 7 post-inoculation. 
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TABLE 3- AGID r esults at each sample col lection p e r i od 
COW DAYS POST-INOCULATION 
0 1 7 21 35 49 63 77 91 
278 NEG NEG NEG NEG POS POS POS POS POS 
57 20 NEG NEG NEG NEG POS POS POS POS POS 
6446 NEG NEG NEG POS POS POS POS POS POS 
6618 NEG NEG NEG POS POS POS POS POS POS 
67 56 NEG NEG NEG POS POS POS POS POS POS 
NEG=Negative AGIO test result POS=Positive AGIO test result 
DAY O=Day of inoculation 
Figure 2 is the agarose gel that was blotted and 
hybri di zed. The posit i ve control band is clearly seen, 
followed by 3 positive samples and 2 negative samples. The x-
ray film of the hybridization of this gel (figure 28) shows 
the positive control band and the 3 positive samples. The 
results of the hybridization show that the bands of DNA that 
were observed on the agarose gel were, indeed, the target 
sequence in the gag region of the BLV genome . 
Figure 3 is an example of 2 agarose gels after 
electrophoresis and staining with ethidium bromide. The DNA 
samples in figure 3A were from samples taken immediately 
before experimental inoculation. Five o f the cows were neg-
ative for BLV by PCR and the other 5 cows were positive on 
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TABLE 4-PCR res ults at each sample collection period 
COW DAYS POST-INOCULATION 
278 
5720 
6446 
6618 
6756 
0 
NEG 
NEG 
NEG 
NEG 
NEG 
1 
NEG 
NEG 
NEG 
NEG 
NEG 
7 
POS 
POS 
POS 
POS 
POS 
21 
POS 
POS 
POS 
POS 
POS 
NEG=Negative PCR test result 
DAY O=Day of inoculation 
35 
POS 
POS 
POS 
POS 
POS 
49 
POS 
POS 
POS 
POS 
POS 
63 
POS 
POS 
POS 
POS 
POS 
77 
POS 
POS 
POS 
POS 
POS 
91 
POS 
POS 
POS 
POS 
POS 
POS=Positive PCR test result 
day zero. Figure 3B is an agarose gel of DNA from cows taken 
on day 7 post-inoculation. Two of the samples on the gel are 
from cattle positive by PCR but negative by AGIO on day 7. The 
fact that all bands observed were at the same position on the 
gel, and the fact that these bands corresponded approximately 
to a band of 344 base pairs on the DNA size standard strongly 
suggest that the amplified DNA that was the 375 base pair 
target sequence in the gag region of the genome. 
The PCR performed on BIV gave negative results. In other 
words, the test using primers specific for BLV did not give a 
false positive result. 
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2 3 • 5 6 8 9 
Fig 2-Agarose gel of PCR-amplified DNA and southern blot of 
this gel. Fig 2A-Agarose gel of PCR-amplified leukocyte DNA . 
· = position of 344 base pair molecular weight standard. Lane 
1 = molecular weight standards, lane 2 = reagent control, lane 
3 = negative control DNA, lane 4 = positive control DNA, lanes 
5,6,7 = BLV positive cattle, lanes 8,9 = BLV negative cattle. 
' -: .·i ~ 
·:i:S. ~ ' ,... . 
~t!~~ :~,;i i:, ~:. :. ;t~·f·~f-~,. ,'.·;,;.. 
Fig 2B-Southern blot of gel in Fig 2A. 
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Fig 3-Agar gel electrophoresis o f PeR-amplified leukocyte DNA 
and control samples from experimentally infected cattle. Fig 
3A-Samples taken on day 0 before inoculation. 
= position of 344 base pair molecular weight standard. Lane 
1 =molecular weight standards, lane 2 = reagent control, lane 
3 = negative control DNA, lane 4 = positive control DNA, lane 
5 = cow # 6508*, lane 6 = cow # 6546*, lane 7 = cow# 6618$, 
lane 8 = cow# 6696*, lane 9 = cow# 6756$, lane 10 = cow# 
6820*, lane 11 =cow# 6516*, lane 12 =cow# 6446$, lane 13 
= cow # 5720$ , lane 14 = cow # 278$. * =positive by both AGIO 
and PCR before inoculation, % = negative by both AGIO and PCR 
before inoculation . 
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2 3 5 6 7 8 9 10 
Fig 3B = PCR amplification of leukocyte DNA at day 7. 
position of 344 base pair molecular weight standard. Lane 
1 = molecular weight standards, lane 2 = reagent control, lane 
3 = negative control DNA, lane 4 = positive control DNA, lane 
5 = cow # 6446@, lane 6 = cow # 6508, lane 7 = cow # 6516, 
lane 8 = cow # 6546, lane 9 = cow # 6618@, lane 10 cow # 
6696 . @ designates cattle positive by PCR but negative by AGIO 
on day 7. 
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DISCUSSION 
This experiment was designed as a pilot study to develop a 
PCR protocol that would be specific for BLV, to compare the 
sensitivity and specificity of this test to the AGIO test, and 
to assess the feasibility of widespread use of the PCR in the 
diagnosis of BLV. 
Because 5 out of the 10 cows used in the study were 
positive for BLV before inoculation, only 5 cows were infected 
with BLV as a result of experimental inoculation. Though 
experimental animal numbers were small, the results do answer 
the hypothesis that the PCR is more sensitive and specific 
than AGIO. 
There are many variables to be addressed in the initial 
development of the PCR protocol. First and foremost is the 
selection of effective primers. Guidelines for primer 
selection have been given elsewhere (literature review section 
in this paper) . Though the primers used in this study are not 
ideal in every aspect, they do have an average G+C content of 
50-60%, they are not complementary to each other, they are not 
palindromic, and there are no stretches of polypurines and 
polypyrimidines within the primers that are longer than 3 base 
pairs. Guidelines have been given for the concentration of all 
the components in the PCR and the cycling conditions. In most 
circumstances, these conditions will be effective when 
amplifying genomic DNA. However, the PCR conditions should be 
optimized. In this experiment, the primers selected the first 
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time were effective, but the PCR conditions needed to be 
optimized. Functional conditions were determined before the 
test was run on the stored experimental samples. 
A PCR protocol was successfully developed for bovine 
l e ukemia virus. Another bovine retrovirus, BIV, was found not 
to give a false positive result to the PCR test developed for 
BLV. Ideally, the PCR test for BLV should be performed on all 
common bovine viruses to ensure that infection with BLV is the 
only way that an animal would be positive to the test. 
An important consideration when developing a PCR protocol 
is the geographic location where the test will be used. The 
primers successfully used in Logan, Utah were not consistently 
successful in Quebec {102) so other primers had to be 
selected. Whether this is an optimization problem of the PCR 
reaction, or whether it reflects regional variations in the 
BLV genome is not clear. To address this question, BLV 
isolates from Quebec and Logan would have to be sequenced and 
the nucleotide sequences compared. 
The 5 cows that were positive before the experimental 
inoculation were kept in the study. They remained positive for 
BLV by AGID and PCR throughout the experiment. These positive 
samples were tested by AGID and PCR concurrently with negative 
samples at the beginning of the study before all the cows 
became positive for BLV. This suggests that there was no 
cross-contamination between samples in the AGID and PCR tests. 
Therefore, the 5 positive cows may have served as quality 
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control, at least in the early stages of the experiment, 
though this was not the original intent when the cows were 
included in the study. Initially, 10 cows that were negative 
for AGIO in the 1989 herd check and that were destined for 
slaughter were chosen to be on the study. Five of the cows 
seroconverted after the 1989 herd test for BLV, so that only 
5 cows were negative for BLV at the start of the study. 
The results of this study indicate that the use of PCR 
provides diagnosis of BLV sooner after infection than the AGIO 
test. 
In this experiment, cows became AGIO-positive between 1 and 
5 weeks post-infection. This is similar to previous work (23) 
in which animals first became AGIO-positive at 5-6 weeks after 
inoculation. 
Naif et al (103) recently used the PCR to detect BLV 
proviral DNA in dairy and beef animals, some of which had 
persistent lymphocytosis and some others had lymphosarcoma. 
They used primers from the env gene in an Australian isolate 
of BLV and amplified a DNA fragment 440 bp in size (103). 
These researchers (103) detected BLV by PCR in animals that 
were AGIO-positive, AGIO-positive with persistent 
lymphocytosis, and AGIO-positive with tumors. They found that 
PCR was negative in AGIO-negative animals, except in 1 case. 
Naif et al (103) concluded that the PCR is a sensitive, fairly 
rapid, and inexpensive test. In another study (104), these 
researchers used the PCR to detect BLV infection in sheep. The 
60 
sheep were infected by intravenous injection of lymphocytes 
from either a cow or a sheep known to be BLV positive (104). 
In one phase of the experiment (104), 4 out of 6 sheep became 
BLV positive by the PCR 1 week after infection, and the other 
2 animals had become BLV positive at 3 weeks post-infection. 
In this s tudy, all 5 cows that were infected became 
positive by the PCR test 7 days post-innoculation. This is 
comparable to the study performed in sheep (104), in which 4 
out of 6 sheep became positive by PCR 1 week post-infection. 
It can, therefore, be concluded that PCR is a more sensitive 
test than the AGIO and can detect infection at least 2 weeks 
before the animal seroconverts. Naif et al (103) found that 1 
AGIO-negative animal was, in fact, BLV-positive by the PCR. 
This suggests that PCR is more specific than AGIO; that is, 
there is more chance of false negatives with the AGIO test. 
Despite the fact that the PCR is highly sensitive and 
specific, relatively quick and easy to perform once the 
protocol has been optimized, relatively inexpensive unless a 
thermal cycler has to be purchased (and this would be a one-
time cost of $3,000 at the very least), theoretically able to 
distinguish an AGIO-positive test result due to colostral 
antibody from that acquired by natural infection (because it 
detects the actual viral DNA), and theoretically able to 
detect virus in milk, it may not be accepted into widespread 
use. There are a number of reasons for this: 
1. The AGIO test is rapid, easy to perform, inexpensive, and 
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is widely us ed and accepted. There is little need for a new 
diagnostic test, at least for herd screening . 
2 . PCR is relatively new technology, and few veterinary 
diagnostic labs have the equipment and expertise to perform 
it. 
The PCR will have its greatest application in testing 
individual animals for specific reasons, such as testing 
animals to be imported or testing suspect animals that are 
AGIO-negative. 
Future research using the PCR in BLV diagnosis could be 
directed towards early confirmation of infection in young 
calves in situations where the AGID test results could be 
confounded by colostral antibody. In addition, detection of 
BLV in milk samples by the PCR would be useful because it is 
often more convenient for dairy producers to collect milk 
samples than blood samples. In these 2 situations, the PCR has 
considerable potential utility. 
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